A novel STING agonist for cancer immunotherapy and a SARS-CoV-2 vaccine adjuvant
- 8 December 2020
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 57 (4) , 504-507
Abstract
A novel STING agonist, CDGSF, ipsilaterally modified with phosphorothioate and fluorine, was synthesized. The phosphorothioate in CDGSF might be a site for covalent conjugation. Injection of CDGSF generated an immunogenic (“hot”) tumor microenvironment to suppress melanoma, more efficiently than dithio CDG. In particular, immunization with SARS-CoV-2 spike protein using CDGSF as an adjuvant elicited an exceptionally high antibody titer and a robust T cell response, overcoming the drawbacks of aluminum hydroxide. These results highlighted the therapeutic potential of CDGSF for cancer immunotherapy and the adjuvant potential of the STING agonist in the SARS-CoV-2 vaccine for the first time.Keywords
Funding Information
- National Natural Science Foundation of China (21672126)
- National Key Research and Development Program of China (2019YFA0904200, 2018YFA0507600)
This publication has 41 references indexed in Scilit:
- pH-Responsive Poly(d,l-lactic-co-glycolic acid) Nanoparticles with Rapid Antigen Release Behavior Promote Immune ResponseACS Nano, 2015
- STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockadeScience Translational Medicine, 2015
- Advances in aluminum hydroxide-based adjuvant research and its mechanismHuman Vaccines & Immunotherapeutics, 2015
- Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer TherapyCancer Cell, 2014
- Synthesis of biotinylated c-di-gmp and c-di-amp using click conjugation.Nucleosides, Nucleotides & Nucleic Acids, 2013
- Simultaneous in vivo tracking of dendritic cells and priming of an antigen-specific immune responseBiomaterials, 2011
- One-Flask Syntheses of c-di-GMP and the [Rp,Rp] and [Rp,Sp] Thiophosphate AnaloguesOrganic Letters, 2010
- STING is an endoplasmic reticulum adaptor that facilitates innate immune signallingNature, 2008
- Type I interferon as a stimulus for cross-primingCytokine & Growth Factor Reviews, 2008
- The tumor‐draining lymph node as an immune‐privileged siteImmunological Reviews, 2006